Traditional methods of compound analysis in the pharmaceutical and dermo-cosmetic industries often lack the biological complexity needed to accurately predict efficacy and toxicity in human skin. Animal models raise ethical concerns and may not fully replicate human skin responses, while conventional in vitro models often lack the multi-cellular interactions necessary for comprehensive analysis.

BioHive provides advanced, customizable in vitro skin organoids that offer a more reliable and biologically relevant platform for compound analysis. Derived from induced pluripotent stem cells (iPSCs), these organoids contain multiple skin cell types, including epidermis, dermis, hair follicles, neurons, and adipocytes, enabling the study of cell-cell interactions and inflammatory signatures. BioHive's technology allows for disease modeling of genetic and inflammatory skin conditions and targeted research for focused efficacy analysis. These skin organoids enhance the robustness of research outcomes, reduce reliance on animal models, and accelerate the development of new pharmaceutical and dermo-cosmetic products.

Skin organoids derived from induced pluripotent stem cells (iPSCs) for unlimited cell source and reproducibility

Inclusion of multiple cell types: epidermis, dermis, hair follicles, neurons, and adipocytes

Customizable organoids to suit specific biological needs

Disease modeling capabilities for genetic and inflammatory conditions

3D imaging for detailed analysis of organoid structure and function

Efficacy and toxicity analysis

Analysis of cell-cell interactions and inflammatory signatures

BioHive's primary customers are in the pharmaceutical and dermo-cosmetic industries, including researchers and product developers focused on skin-related drug discovery, toxicity testing, and cosmetic ingredient development.